A field once taught that IgA nephropathy was benign now faces a wave of new therapies. The panel frames why this is a defining moment and where the real uncertainty lies.

IgA nephropathy is common to specialists but rare to the physicians who see patients first. The panel examines why the disease is caught late and what screening and education could change.

"When to Biopsy in IgAN: Presentation, Thresholds, and Monitoring" takes up the question of which patients warrant a diagnostic biopsy.

In "IgAN Biopsy Interpretation: Beyond the Oxford Classification," our experts turn to how much a pathology score should drive decisions.

This episode, "Biomarkers in IgAN: Why Hematuria and GFR Slope Matter," features the panel scrutinizing the tools they rely on.

In "2025 KDIGO Updates in IgAN: Dual Pathways and New Targets," the panel examines the guideline changes reshaping practice.

This episode, "Optimized Supportive Care in IgAN: Salt, Blood Pressure, and Proteinuria," features Dr. Fervenza pressing on the fundamentals.

In "How You Lower Proteinuria in IgAN: Immunologic vs Hemodynamic," the panel draws a distinction that reshapes treatment goals.

In "IgAN Pathogenesis and the Rationale for Complement Inhibition," our experts connect disease mechanism to drug targets.

This episode, "Complement Inhibition in IgAN: Interpreting the APPLAUSE Trial," features the panel weighing a landmark trial.

In "Endothelin Receptor Antagonists in IgAN: The ALIGN Trial and Access," our experts turn to a newly approved kidney-protective class.

This episode, "B-Cell Therapy in IgAN: APRIL, BAFF, and the VISIONARY and ORIGIN Trials," features the panel examining a class that changed the field.